

## CASE REPORT

# Solid Pseudopapillary Neoplasm of the Pancreas - A Report of Two Cases and a Short Review of the Current Literature

Eirini Pantiora<sup>1</sup>, Antonios Vezakis<sup>1</sup>, Dimitra Kollia<sup>1</sup>, Eleni Karvouni<sup>2</sup>, Aikaterini N Politi<sup>2</sup>,  
Elissaios A Kontis<sup>1,4</sup>, Andreas Polydorou<sup>1</sup>, Georgios P Fragulidis<sup>1</sup>

2nd Department of <sup>1</sup>Surgery, <sup>2</sup>Pathology, and <sup>3</sup>Cytology, "Aretaieio" Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

<sup>4</sup>Institute of Liver Studies, King's College Hospital, London, United Kingdom

### ABSTRACT

**Context** Solid pseudopapillary neoplasms of the pancreas are mainly found in females and account for <2% of pancreatic tumors. They have nonspecific clinical presentation with vague radiologic features and are often histologically benign. Despite the uncertain histogenesis and the low grade of malignancy, these neoplasms present a select panel of immunostains which advantage pathologists to differentiate from other tumors of the pancreas. The current study aims to present the treatment of 2 cases of solid-pseudopapillary neoplasm of the pancreas in our hospital and a literature review on the topic. **Case report** Both patients were females with a mean tumor size of 5 cm. Preoperative diagnosis was based on distinctive features of the neoplasm in fine needle aspiration cytology in one patient. The two procedures performed were enucleation of the tumor and a distal pancreaticosplenectomy. Both patients are on a regular follow up and no recurrence has been detected 2 years after surgery. **Conclusions** It is important to differentiate solid pseudopapillary neoplasms from other pancreatic neoplasms because of the low potential for malignancy and a favorable prognosis. Fine needle aspiration cytology is the most valuable tool for diagnosis and surgical planning. Surgery is the primary therapeutic modality and in patients with distant metastasis or adjacent organ invasion aggressive approach should be considered. Local resection or enucleation can be performed for small tumors in selected cases. There are limited data about chemotherapy and radiotherapy modalities due to the availability of limited case series or reports only. Despite the excellent prognosis, the inability to predict malignant behavior mandates a long-term follow-up post-surgery.

### INTRODUCTION

Solid pseudopapillary neoplasm of the pancreas (SPNP) is one of the unusual histopathological variants accounting for <2% of pancreatic neoplasms, which predominantly affect young females. It was first termed by Dr. Virginia Franz in 1959 as a "papillary tumor of the pancreas with solid and cystic components" in the Armed Forces Institute of Pathology, questioning its nature to be either benign or malignant. The patient was a 2-year-old boy who died during an attempted pancreaticoduodenectomy [1, 2].

In 1970, Hamoudi described the ultrastructural features of the tumor, which led to its acceptance as a separate clinic pathological entity [3]. Next, the tumor has been named using different terminologies until the World Health Organization (WHO) adopted the term "solid pseudopapillary tumor or neoplasm" in 1996 [4]. It was finally defined as a "low-grade malignant neoplasm of the exocrine pancreas" in the current WHO classification in 2010 [5]. Nevertheless, the term SPNP gained wide acceptance and nowadays is the commonly used name for this entity.

The typical patient is a female in the third decade of life presenting with pain and/or palpable mass in about 90% of cases [6, 7]. About 15% of the patients are asymptomatic before clinical detection; however, with the increased use of cross-sectional imaging an increasing number of cases are being detected incidentally in asymptomatic patients. Pancreatic body and tail are the most common sites of presentation but also can be found in head and uncinat process in 36% of cases [8]. Classic imaging characteristics include large size, mixed solid and cystic nature, encapsulation, hemorrhage and occasional

Received June 16th, 2018 – Accepted August 08th, 2018  
**Keywords** Diagnosis; Pancreatic Neoplasms; surgery  
**Abbreviations** SPNP solid pseudopapillary neoplasm of the pancreas;  
MRI magnetic resonance imaging  
**Correspondence** Georgios P Fragulidis  
2nd Department of Surgery  
Aretaieio Hospital, University of Athens Medical School,  
76, Vas.Sophias Ave., 11528, Athens, Attica, Greece  
**Phone** +30 6972 910955  
**Fax** +30 210 9690184  
**E-mail** gfragulidis@aretaieio.uoa.gr

calcification without ductal dilatation or atrophy of pancreatic parenchyma [2, 8]. When these features are encountered in a young female patient, SPNP should be included in differential diagnosis. Considered to be a low-grade malignant tumor, with an incidence of malignant transformation of around 15%, surgical resection is the treatment of choice. Nevertheless, since SPNP may exhibit features such as local invasion, metastases or recurrence in up to 20% of cases, an intensive follow-up is highly recommended [7].

Herein we present the management of two patients diagnosed with SPNP in our hospital and a short review of the current literature regarding this rare disease.

### Case #1

A fifty-three-year-old female patient presented for routine follow up after breast-conserving surgery due to DCIS 4 years prior. Abdominal CT revealed a 5.5 × 3.7 × 5.3 cm pancreatic tail solid and cystic tumor in contact with left renal vein and splenic vein. An enhancement of the solid component and mass capsule along with a small calcification was noted on tumor imaging (Figure 1). The patient underwent distal pancreatectomy and splenectomy. Histological examination showed solid pseudopapillary pancreatic tumor (Figure 2a). On microscopy some of the tumor cells appear with a foamy cytoplasm and others characterized as “bizarre degenerated nuclei” with plenty

eosinophilic cytoplasm (Figure 2b). Evaluation of the tumor immunohistochemical expression status revealed alpha-1-antitrypsin and a-1-antichymotrypsin (moderate), b-catenin with nuclear and cytoplasmic positivity, and CD10, CD56, NSE, E-cadherin positive reactive (Figure 3). The Ki-67 index was ≈2%. There was no lymph node infiltration. Postoperative course was uneventful and the patient was discharged from the hospital on the 5th postoperative day. The patient is on a regular follow up and has no recurrence 4 years after surgery.

### Case #2

A forty-one-year-old female patient presented with a dull epigastric pain for approximately two months. She had no significant past medical history and she was not on any medication. A C/T scan and MRI imaging revealed a 4.9 × 4 × 4.2 cm tumor mass located in the pancreatic head (Figures 4a and 4b). There was no dilatation of the main pancreatic duct. During preoperative evaluation, endoscopic ultrasound-guided fine needle (EUS-FNA) aspiration biopsy and fine-needle aspiration cytology (FNAC) was performed (Figures 4c and 4d). Immunohistochemical stains, confirmed the cytological impression of SPNP (Figure 5). Patient underwent enucleation of the pancreatic tumor mass, which was completed uneventfully. Frozen section of the specimen revealed an ambiguous result between SPNP and neuroendocrine tumor. On permanent section




Figure 1. Contrast Enhanced Computed Tomography images. (a). Multiplanar reconstruction; (b). Coronal; (c). Sagittal reconstructions show a large (5.5 cm) solid and cystic mass (\*) in the pancreatic tail. Images reveal enhancement of the solid component and mass capsule. A small calcification is visible in the mass







Figure 2. Solid pseudopapillary neoplasm of the pancreas. (a). Solid area composed of closely packed sheets of pseudopapillae, (H-E X200); (b). Presence of rare bizarre degenerated nuclei (arrows), (H-E X400)



**Figure 3.** Solid pseudopapillary neoplasm of the pancreas. **(a).** Positive cytoplasmic immunohistochemical staining for CD 56; **(b).** Positive nuclear immunohistochemical staining for  $\beta$ -catenin in the majority of tumor cells (X200)




**Figure 4.** **(a, b).** Axial CT slices show a hypodense pancreatic mass (white star); **(c, d).** Endoscopic ultrasound images. The mass (white star) is hypoechoic. Yellow arrow: Biopsy needle



**Figure 5.** Solid pseudopapillary neoplasm of the pancreas, (EUS-FNAC direct smear). **(a).** Cellular smear composed of small, uniform cells, lying in a meshwork of blood vessels, (Papanicolaou stain X 100); **(b).** Neoplastic cells showing positive nuclear staining for b-catenin, (peroxidase anti-peroxidase X200); **(c).** Area of cystic degeneration, (Papanicolaou stain X 200)

pathology, the tumor was well defined with solid and cystic areas without any mitotic activity with cystic degeneration and vacuolization. Immunohistochemical examination was positive for b-catenin (nuclear staining), progesterone

receptors (PgR), CD56, Vimentin and focal positive for Synaptophysine (**Figure 6**). The final pathology report revealed a SPNP. She is doing well afterwards and the patient's 2-year follow up is currently expected.



**Figure 6.** Solid pseudopapillary neoplasm of the pancreas. **(a).** Strong immunohistochemical expression for vimentin (X400); **(b).** Strong nuclear immunohistochemical expression for progesterone receptors (X400). **(c).** Rare tumor cells expressing synaptophysin (X200)

## DISCUSSION

Mostly found incidentally on radiologic examination, SPNP is extremely rare disease presented in young women within the second or third decade of life [2, 7, 8]. They account for 1-2% of all exocrine pancreatic tumors, but 52-71% of pancreatic tumors in children and adolescents [6]. Few cases have been reported in men [9]. Choi *et al.* found that children with SPNP with a median age of 13 years old presented as adolescents and were mostly female in 78% [10]. More recent studies suggest a lower female predominance of SPNP in children, with male-to-female ratios that can approach, 1:1.75, instead of the 1:9.78 reported for all age groups [11, 12]. The most commonly reported complaint patient present is the diffuse nonspecific abdominal pain and discomfort later in the course of the disease due to the tumor enlargement causing a mass effect [2, 13]. Lee *et al* compared the clinical features of adults and children with SPNP. In the adult group, the diagnosis was usually made incidentally during screening with detection of a mass. By contrast, all of the children were symptomatic [14]. Leraas *et al.* evaluate a national combined cohort of pediatric and adult patients with SPNP. They found that children with SPNP have similar disease severity at presentation, receive similar treatments, and demonstrate equivalent postoperative outcomes compared with their adult counterparts [15].

The initial diagnosis of SPNP relies mostly on imaging, as there are no specific tumor markers for this entity. However, diagnosis with imaging alone is technically challenging in small tumors and in those without cystic component. Other major pancreatic cystic neoplasms should be taken into considerations, such as a pancreatic cyst, cystadenocarcinoma, islet cell tumor or neuroendocrine tumor. The presence of SPNP is highly suggested when certain pathognomonic features are identified on CT scan: well-defined, encapsulated mass with cystic and solid component, areas of central calcification, necrosis or hemorrhage. Tumors are encapsulated and usually well demarcated. Tumor capsule as well as the solid part enhance after intravenous contrast administration to a degree similar to normal pancreatic tissue during both arterial and venous phases. Calcification found approximately in one third of cases, usually peripheral and less common at the central part of the mass as in

our case [16]. Occasionally, intra tumor hemorrhage or a fluid-debris level is depicted [17]. On magnetic resonance imaging (MRI) these tumors have characteristic properties, such as heterogeneous high signal intensity on T2-weighted images and an early peripheral heterogeneous enhancement on dynamic contrast enhanced imaging [2]. The role of positron emission tomography has not been established yet in the diagnostic algorithm of SPNP, as these tumors are usually benign [18].

The uncertain histogenesis and the low grade of malignancy make these neoplasms strongly interesting for medical research. Despite numerous investigations, the cellular origin of the tumors is unclear but they possibly originate from the multipotent primordial cells and lack certain endocrine and exocrine differentiation [19]. Other common theories suggest the origin to be from the ductal epithelium, neuroendocrine cells, or possibly extrapancreatic genital ridge angle. Regardless the association of the disease with young women, there are no reports suggesting connection with endocrine disturbances although progesterone receptor positivity is seen in almost all cases of SPN irrespective of sex [20]. Distinctive molecular alterations such as the presence of somatic-catenin coding gene (CTNNB1) mutations, the gene encoding b-catenin in Wnt signaling pathway, are demonstrated in almost all cases [7]. These changes will be detected by strong nuclear staining of b-catenin. Recent investigations on cellular signaling have successfully demonstrated that activation of the Wnt/b-catenin pathway in these tumors is associated with the up regulation of genes required in Notch, Hedgehog, and androgen receptor signaling pathways [21]. Guo *et al.* detected that CTNNB1 mutations were presented throughout all of their patients studied (100%), and a higher count of single nucleotide polymorphisms (SNPs) was particularly detected in patients with older age, larger tumor, and metastatic disease [22]. No other genetic alterations, such as KRAS, TP53, and SMAD4, which are established in ductal adenocarcinoma, are involved in SPNP, demonstrating its different nature from other pancreatic neoplasms.

The cells of SPNP demonstrate strong positive staining for CD10, vimentin, a-1-antitrypsin, a-1-antichymotrypsin, neuron-specific enolase, and cyclin D1. Some cases of SPNP present neuroendocrine immunostaining by consistent staining with CD56 and focal reactivity for synaptophysin,

as in our patients' immune profiles. Due to these staining characteristics, fine-needle aspiration cytology (FNAC) is helpful for making a diagnosis preoperatively to perform the appropriate surgery [6, 23]. EUS-FNAC demonstrates improved sensitivity for diagnosing SPNP of the pancreas in adults, correctly identifying over 80% of patients with SPNP [24, 25].

Although the malignant potential is low, up to 15% of SPNP patients develop metastasis. According to WHO, perineural, pancreatic paranchymal or lymphovascular invasions are predictive factors for aggressive behavior [5, 13]. In addition, factors such as male gender, younger age, large tumor size (>5 cm), capsule invasion, and elevated mitotic rate are suggestive in the literature to result in increased malignant behavior [26, 27]. The most common metastatic sites of the SPNP are the liver, regional lymph nodes, mesocolon, omentum and peritoneum [28]. The lung is a very rare metastatic site and was found in only three cases in the literature [7, 29].

First choice of treatment remains complete surgical resection since SPNP is limited to the pancreas in over 95% of its patients and can be radically resected. However, it should be noted that SPNP is clearly a malignant neoplasm with local and metastatic potential. Thus, there is debate about the optimum extent and type of surgical operation for SPNP [30]. In the majority of cases aggressive resection offers an excellent prognosis and a long survival. In case of patients with suspected lymph nodes, lymphadenectomies must be performed in order to avoid relapses [13, 31, 32]. Since these are low-grade tumors and especially surrounded by a fibrous capsule, some surgeons advocate simple enucleation of the lesion. Although still relatively rare, the number of pancreatic parenchyma-sparing operations performed for SPNP has doubled over the last years and account for almost 15% of all pancreatic resections [30]. Because it is a low-grade malignant tumor, usually occurring in young and healthy patients with a long life expectancy, parenchyma-preserving procedures are worthwhile especially to avoid exocrine and endocrine insufficiency. Pancreatic enucleations and central pancreatectomies compared to standard resections have comparable short-term outcomes regarding morbidity and mortality [33, 34]. One of the critical questions when considering parenchymal-sparing surgery in patients with SPNP is the risk of lymph node metastases. Overall, lymph node involvement was reported to be almost 2.0% in a review study by Law *et al.* ranging from 0.5 to 2.2% [30]. The number of lymph nodes examined at surgery has been shown to influence the staging in patients with pancreatic ductal adenocarcinoma, where patients with fewer than 12 lymph nodes found to be understaged [35]. Thus, local resection or enucleation can be performed for small tumors in selected cases of SPNP. When considering enucleation to avoid extensive procedures, the size of the tumor, well-defined margin and distance to the main pancreatic duct and/or common bile duct should be carefully assessed [33, 36]. A recent study by Wang *et al.* comparing enucleation of the SPNP with conventional pancreatic resection revealed

that enucleation was associated with a low rate of severe postoperative morbidity and no increased risk of tumor recurrence. Moreover, enucleation had a lower rate of postoperative long-term exocrine insufficiency compared with conventional resection of the pancreas, although the difference was non-significant [36].

The role of neoadjuvant and adjuvant therapy in the treatment of SPNP is unclear [19]. Studies have demonstrated a role for gemcitabine and radiotherapy either to downsize large tumors or to treat the rare case of unresectable disease [37, 38, 39, 40, 41, 42]. Intra-arterial chemoembolization in patients with multiple hepatic metastases, radiofrequency ablation and liver transplantation has also been used in patients with unresectable liver metastasis to extend survival [19, 43, 44]. Recurrence with peritoneal carcinomatosis in SPNP is very rare and is predominately caused by accidentally rupture during surgery [32]. The treatment strategies of SPNP with peritoneal metastases reported in review articles include cytoreductive surgery (CRS), complete cytoreductive surgery (CCRS), and HIPEC [31, 32, 45]. The value of chemotherapy for patients with SPNP is not well studied and remains unknown. Since the period of recurrences ranges in years and the recurrences (local or metastatic) usually being resectable, the role of adjuvant treatment is uncertain and often redundant. There are few studies that have addressed the use of adjuvant therapy for patients with SPNP using various chemotherapy regimens based upon cisplatin, oxaliplatin, cyclophosphamide, adriamycin, 5 FU, etoposide, and gemcitabine [19]. The two most commonly used chemotherapeutic agents were 5-Fluorouracil and gemcitabine, while Kang *et al.* showed that cisplatin was the most potent drug for these tumors [46]. However, the small numbers of cases make it difficult to draw any conclusions on the role of adjuvant therapy or the optimal type of therapy for SPNP [30]. Therefore, the decision to consider any adjuvant treatment for SPNP with rare aggressive behavior in un-resectable or recurrent cases is on physician's discretion. Recently, a pyrosequencing of the SPNP antecedent to metastasis showed an uncommon EGFR mutation at L861Q in the kinase domain of exon 21 [47]. Confirmation of this finding in future studies could support preoperative testing for EGFR mutation analysis to detect aggressive SPNP and treatment response using EGFR inhibitors. Nevertheless, taking into consideration the slow progression of the tumor and the high rate of resectability, resection of recurrences and metastases can offer good long-term survival [48]. In contrast to other pancreatic tumors, aggressive surgical resection is reasonable even in the presence of recurrence or limited metastases and invasion of the portal vein or superior mesenteric artery does not indicate tumor unresectability. Thus, every effort should be made to obtain a preoperative diagnosis in these settings. Since all recurrences occurred more than 5 years after curative resection, patients should undergo > 5 year follow-up surveillance with routine imaging [49]. Because of rarity of SPNP, its indolent character and based on the literature results, the length of surveillance to at least 10

years is warranted. Nevertheless, evaluations of these patients with a C/T scan each year for the first 5 years of follow up is a reasonable option.

In conclusion, SPNP is a rare disease with atypical clinical symptoms an indolent clinical course. The characteristic imaging features though, can help to make the correct diagnosis and differentiate from other pancreatic tumors. FNAC and cytomorphological recognition of this tumor is the most valuable tool for diagnosis and surgical planning. Surgery is the primary therapeutic modality and in patients with distant metastasis or adjacent organ invasion aggressive approach should be considered. Despite the excellent prognosis, with a 5-year survival rate of ~95%, the inability to predict malignant behavior mandates a long-term follow-up post-surgery. At present, there is a definite role of both neoadjuvant chemotherapy and radiotherapy in selected cases.

---

## Conflict of Interest

The authors declare no conflict of interest.

---

## References

1. Frantz VK. Tumors of the pancreas. In: Bumberg CW, editor. Atlas of tumor pathology. VII. Fascicles 27 and 28. Washington: Armed Forces Institute of Pathology 1959; p. 32-39.
2. El imad T, Haddad F, Kesavan M, Deeb L, Andrawes S. Solid pseudopapillary tumor of the pancreas: an unusual cause of abdominal pain. *Cureus* 2017; 9:e1252. [PMID: 28649475]
3. Hamoudi AB, Misugi K, Grosfeld JL, Reiner CB. Papillary epithelial neoplasm of pancreas in a child. Report of a case with electron microscopy. *Cancer* 1970; 26:1126-1134. [PMID: 5476792]
4. Kloppel G, Solcia E, Longnecker DS, Capella C, Sobin LH. Histological typing of tumours of the exocrine pancreas. In: Klöppel G, Solcia E, Longnecker DS, Capella C, SOBIN LH, eds. World Health Organization International Classification of Tumours. 2nd ed. Berlin : Springer-Verlag, 1996.
5. Klöppel G, Hruban RH, Klimstra DS, Maitra A, Morohoshi T, Notohara K, et al. Solid-pseudopapillary tumor of pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. World Health Organization Classification of Tumours of the digestive system. Lyon: IARC Press; 2010; 327-330. [NLMID: 101553728]
6. Mahida JB, Thakkar RK, Walker J, Shen R, Kenney BD, Prasad V, et al. Solid pseudopapillary neoplasm of the pancreas in pediatric patients: A case report and institutional case series. *J Ped Surg Case Reports* 2015; 3:149-153.
7. Dinarvand P, Lai J. Solid Pseudopapillary Neoplasm of the Pancreas: A Rare Entity With Unique Features. *Arch Pathol Lab Med* 2017; 141:990-995. [PMID: 28661210]
8. Reindl BA, Lynch DW, Jassim AD. Aggressive variant of a solid pseudopapillary neoplasm: a case report and literature review. *Arch Pathol Lab Med* 2014; 138:974-978. [PMID: 24978926]
9. Lima CA, Silva A, Alves C, Alves A Jr, Lima S, Cardoso E, et al. Solid pseudopapillary tumor of the pancreas: Clinical features, diagnosis and treatment. *Rev Assoc Med Bras (1992)* 2017; 63:219-223. [PMID: 28489126]
10. Choi SH, Kim SM, Oh JT, Park JY, Seo JM, Lee SK. Solid pseudopapillary tumor of the pancreas: a multicenter study of 23 pediatric cases. *J Pediatr Surg* 2006; 41:1992-1995. [PMID: 17161189]
11. Speer AL, Barthel ER, Patel MM, Grikscheit TC. Solid pseudopapillary tumor of the pancreas: a single-institution 20-year series of pediatric patients. *J Pediatr Surg* 2012; 47:1217-1222. [PMID: 22703796]
12. Tucker SM. Pediatric Neoplasms of the Pancreas: A Review. *Ann Clin Pathol* 2014; 2:1017.
13. Alves JR, Amico EC. Solid-Pseudopapillary Neoplasm of the Pancreas: Case Series and Literature Review. *JOP. J Pancreas (Online)* 2015; 16:218-226.
14. Lee SE, Jang JY, Hwang DW, Park KW, Kim SW. Clinical features and outcome of solid pseudopapillary neoplasm: differences between adults and children. *Arch Surg* 2008; 143:1218-1221. [PMID: 19075175]
15. Leraas HJ, Kim J, Sun Z, Ezekian B, Gulack BC, Reed CR, et al. Solid Pseudopapillary Neoplasm of the Pancreas in Children and Adults: A National Study of 369 Patients. *J Pediatr Hematol Oncol* 2018; 40:e233-e236. [PMID: 29240036]
16. Anil G, Zhang J, Al Hamar NE, Nga ME. Solid pseudopapillary neoplasm of the pancreas: CT imaging features and radiologic-pathologic correlation. *Diagn Interv Radiol* 2017; 23:94-99. [PMID: 28089954]
17. Sunkara S, Williams TR, Myers DT, Kryvenko ON. Solid pseudopapillary tumours of the pancreas: spectrum of imaging findings with histopathological correlation. *Br J Radiol* 2012; 85:1140-1144. [PMID: 22514105]
18. Santhosh S, Lakshmanan RK, Sonik B, Padmavathy R, Gunaseelan RE. Contrast-enhanced fluorodeoxyglucose positron emission tomography/computed tomography in solid pseudopapillary neoplasm of the pancreas. *Indian J Nucl Med* 2016; 31:131-133. [PMID: 27095862]
19. Bansal A, Kaushal V, Kapoor R. Solid pseudopapillary tumors of the pancreas: Is there a role for adjuvant treatment? *Saudi Surg J* 2016; 4:47-51.
20. Weindel M, Zulfiqar M, Bhalla A, Shidham VB. Molecular diagnostics in the neoplasms of the pancreas, liver, gall bladder, and extrahepatic biliary tract. *Clin Lab Med* 2013; 33:875-880. [PMID: 24267192]
21. Terris B, Cavard C. Diagnosis and molecular aspects of solid-pseudopapillary neoplasms of the pancreas. *Semin Diagn Pathol* 2014; 31:484-490. [PMID: 25524568]
22. Guo M, Luo G, Jin K, Long J, Cheng H, Lu Y, et al. Somatic Genetic Variation in Solid Pseudopapillary Tumor of the Pancreas by Whole Exome Sequencing. *Int J Mol Sci* 2017; 18:E81. [PMID: 28054945]
23. Singh A, Mohan G, Chaturvedi S, Sarangi L. Solid pseudopapillary tumor of pancreas: A lesser known entity-diagnosis and pitfalls: A case report. *J Cytol* 2016; 33:229-232. [PMID: 28028341]
24. Law JK, Stoita A, Weaver W, Gleeson FC, Dries AM, Blackford A, et al. Endoscopic ultrasound-guided fine needle aspiration improves the pre-operative diagnostic yield of solid-pseudopapillary neoplasm of the pancreas: an international multicenter case series (with video). *Surg Endosc* 2014; 28:2592-2598. [PMID: 24718662]
25. Hosokawa I, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, Furukawa K, et al. Preoperative diagnosis and surgical management for solid pseudopapillary neoplasm of the pancreas. *J Hepatobiliary Pancreat Sci* 2014; 21:573-578. [PMID: 24535774]
26. Ugras N, Yerci Ö, Coşkun SK, Ocakoğlu G, Sarkut P, Dündar HZ. Retrospective analysis of clinicopathological features of solid pseudopapillary neoplasm of the pancreas. *Kaohsiung J Med Sci* 2016; 32:356-361. [PMID: 27450024]
27. Lubezky N, Papoulas M, Lessing Y, Gitstein G, Brazowski E, Nachmany I, et al. Solid pseudopapillary neoplasm of the pancreas: Management and long-term outcome. *Eur J Surg Oncol* 2017; 43:1056-1060. [PMID: 28238521]
28. Guo X, Li N, Ren K, Wu L, Ma LI, Wu S, et al. Extrapancratic solid pseudopapillary tumors: A clinicopathological analysis of two cases. *Mol Clin Oncol* 2016; 4:845-850. [PMID: 27123293]
29. Lee HS, Kim HK, Shin BK, Choi JH, Choi YJ, Kim HY. A rare case of recurrent metastatic solid pseudopapillary neoplasm of the pancreas. *J Pathol Transl Med* 2017; 51:87-91. [PMID: 27498546]
30. Law JK, Ahmed A, Singh VK, Akshintala VS, Olson MT, Raman SP, et al. A systematic review of solid-pseudopapillary neoplasms: are these rare lesions? *Pancreas* 2014; 43:331-337. [PMID: 24622060]

31. Kim MJ, Choi DW, Choi SH, Heo JS, Sung JY. Surgical treatment of solid pseudopapillary neoplasms of the pancreas and risk factors for malignancy. *Br J Surg* 2014; 101:1266-1271. [PMID: 25052300]
32. Wu J, Tian X, Liu B, Li C, Hao C. Features and treatment of peritoneal metastases from solid pseudopapillary neoplasms of the pancreas. *Med Sci Monit* 2018; 24:1449-1456. [PMID: 29524354]
33. Namur GN, Ribeiro TC, Souto MM, Figueira ER, Bacchella T, Jureidini R. Minimally invasive surgery for pseudopapillary neoplasm of the pancreas. *Arq Bras Cir Dig* 2016; 29: 97-101. [PMID: 27438035]
34. Hüttner FJ, Koessler-Ebs J, Hackert T, Ulrich A, Büchler MW, Diener MK. Meta-analysis of surgical outcome after enucleation versus standard resection for pancreatic neoplasms. *Br J Surg* 2015; 102:1026-36. [PMID: 26041666]
35. Slidell MB, Chang DC, Cameron JL, Wolfgang C, Herman JM, Schulick RD, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. *Ann Surg Oncol* 2008; 15:165-74. [PMID: 17896141]
36. Wang X, Chen YH, Tan CL, Zhang H, Xiong JJ, Chen HY, et al. Enucleation of pancreatic solid pseudopapillary neoplasm: Short-term and long-term outcomes from a 7-year large single-center experience. *Eur J Surg Oncol* 2018; 44:644-650. [PMID: 29525465]
37. Maffuz A, Bustamante Fde T, Silva JA, Torres-Vargas S. Preoperative gemcitabine for unresectable, solid pseudopapillary tumour of the pancreas. *Lancet Oncol* 2005; 6:185-186. [PMID: 15737835]
38. Kanter J, Wilson DB, Strasberg S. Downsizing to resectability of a large solid and cystic papillary tumor of the pancreas by single-agent chemotherapy. *J Pediatr Surg* 2009; 44:e23-25. [PMID: 19853735]
39. Soloni P, Cecchetto G, Dall'igna P, Carli M, Toffolutti T, Bisogno G. Management of unresectable solid papillary cystic tumor of the pancreas. A case report and literature review. *J Pediatr Surg* 2010; 45:e1-6. [PMID: 20438906]
40. Zauls JA, Dragun AE, Sharma AK. Intensity-modulated radiation therapy for unresectable solid pseudopapillary tumor of the pancreas. *Am J Clin Oncol* 2006; 29:639-640. [PMID: 17149006]
41. Das G, Bhuyan C, Das BK, Sharma JD, Saikia BJ, Purkaystha J. Spleen-preserving distal pancreatectomy following neoadjuvant chemotherapy for papillary solid and cystic neoplasm of pancreas. *Indian J Gastroenterol* 2004; 23:188-189. [PMID: 15599007]
42. Fried P, Cooper J, Balthazar E, Fazzini E, Newall J. A role for radiotherapy in the treatment of solid and papillary neoplasms of the pancreas. *Cancer* 1985; 56:2783-2785. [PMID: 4052952]
43. Łągiewska B, Pacholczyk M, Lisik W, Cichocki A, Nawrocki G, Trzebiecki J, et al. Liver transplantation for nonresectable metastatic solid pseudopapillary pancreatic cancer. *Ann Transplant* 2013; 18:651-653. [PMID: 24280737]
44. Prasad TV, Madhusudhan KS, Srivastava DN, Dash NR, Gupta AK. Transarterial chemoembolization for liver metastases from solid pseudopapillary epithelial neoplasm of pancreas: A case report. *World J Radiol* 2015; 7:61-65. [PMID: 25825635]
45. Honore C, Goere D, Dartigues P, Burtin P, Dumont F, Elias D. Peritoneal carcinomatosis from solid pseudopapillary neoplasm (Frantz's tumour) of the pancreas treated with HIPEC. *Anticancer Res* 2012; 32:1069-1073. [PMID: 22399634]
46. Kang CM, Kim H, Cho Y, Kim YS, Hwang HK, Choi HJ, et al. In vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) in solid pseudopapillary tumor of the pancreas. *Pancreas* 2012; 41:498-500. [PMID: 22415673]
47. Neill KG, Saller J, Al Diffalha S, Centeno BA, Malafa MP, Coppola D. EGFR L861Q Mutation in a metastatic solid-pseudopapillary neoplasm of the pancreas. *Cancer Genomics Proteomics* 2018; 15:201-205. [PMID: 29695402].
48. Serrano PE, Serra S, Al-Ali H, Gallinger S, Greig PD, McGilvray ID, et al. Risk factors associated with recurrence in patients with solid pseudopapillary tumors of the pancreas. *JOP* 2014; 15:561-568. [PMID: 25435571]
49. Punch C, Garg N, Harris P. Recurrence of solid pseudopapillary tumor: a rare pancreatic tumor. *Case Rep Oncol Med* 2016; 2016:7523742. [PMID: 27994898]